4-496: Becaplermin , sold under the brand name Regranex , is a cicatrizant , available as a topical gel . Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. It is also known as "platelet-derived growth factor BB". Becaplermin is used for the treatment of diabetic foot ulcers . Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and
8-568: Is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System , a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup D03 is part of the anatomical group D Dermatologicals . Codes for veterinary use ( ATCvet codes ) can be created by placing the letter Q in front of
12-406: The ulcers healed on average 6 weeks faster. Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care. The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and
16-554: Was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. Becaplermin must not be used at the site of a skin cancer . The most common side effects in clinical studies were erythematous rashes . A boxed warning has been added to the US FDA prescription label to describe an increase rate of death from cancer when three or more tubes are used. Cicatrizant ATC code D03 Preparations for treatment of wounds and ulcers
#669330